研究员,药代动力学人工智能建模/Research Investigator,DMPK AI modeler(博士)当面告知
百濟神州有限公司
2026-12-15 15:28:34
校招博士27届
岗位详情
地区:
北京
·
上海
专业要求:
生物信息学数据科学生物统计学
岗位职责:
General Description:
This role will contribute to AI-enabled ADME and translational modeling within the DMPK function, developing and applying predictive and mechanistic modeling approaches to support molecule optimization, candidate selection, and translational decision-making across discovery and preclinical development programs.
Working at the intersection of DMPK, data science, and translational pharmacology, the successful candidate will integrate AI/ML, IVIVE, PK/PD, and PBPK methodologies to improve the prediction of pharmacokinetic behavior and enable data-driven decisions. The role requires strong cross-functional collaboration and the ability to translate complex analyses into clear scientific recommendations that advance project objectives.
Education Required:
PhD in pharmaceutical sciences, pharmacology, computational biology, bioinformatics, biostatistics, computational chemistry, artificial intelligence, machine learning, data science, engineering, or a related quantitative and life sciences discipline.
招聘要求:
General Description:
This role will contribute to AI-enabled ADME and translational modeling within the DMPK function, developing and applying predictive and mechanistic modeling approaches to support molecule optimization, candidate selection, and translational decision-making across discovery and preclinical development programs.
Working at the intersection of DMPK, data science, and translational pharmacology, the successful candidate will integrate AI/ML, IVIVE, PK/PD, and PBPK methodologies to improve the prediction of pharmacokinetic behavior and enable data-driven decisions. The role requires strong cross-functional collaboration and the ability to translate complex analyses into clear scientific recommendations that advance project objectives.
Education Required:
PhD in pharmaceutical sciences, pharmacology, computational biology, bioinformatics, biostatistics, computational chemistry, artificial intelligence, machine learning, data science, engineering, or a related quantitative and life sciences discipline.
公司介绍

百濟神州有限公司
百濟神州有限公司,成立于2018-06-28,位于香港,登记状态:仍注册,注册资本15.4142万美元,公司类型:中外合资
百济神州有限公司是一家商业化阶段的生物技术公司,专注于开发及商业化用于治疗癌症的创新型分子靶向及肿瘤免疫治疗药物。百济神州拥有广泛全面的产品组合。其产品包括六种内部开发、临床阶段的候选药物,其中包括三种后期临床候选药物,zanubrutinib(BTK抑制剂),tislelizumab(PD-1抗体)与pamiparib(PARP抑制剂)。百济神州亦获得五种药物及在研药物的授权许可,包括三种已于中国销售的由新基独家授权的药物ABRAXANE、REVLIMID 及VIDAZA,及两种临床阶段的在研药物,该种药物已获得于中国及亚太地区的其他指定国家开发及商业化的权利。百济神州于2010年于北京成立并在2016年2月在美国纳斯达克全球精选市场上市。截至2018年7月,公司拥有一支超过1300名员工的全球团队,成为一家拥有涵盖研究、临床开发、生产及商业化的全面实力的全球生物技术公司。